ATE111459T1 - Verfahren zur lactonisierung von mevinsäuren und deren analogen. - Google Patents

Verfahren zur lactonisierung von mevinsäuren und deren analogen.

Info

Publication number
ATE111459T1
ATE111459T1 AT89201879T AT89201879T ATE111459T1 AT E111459 T1 ATE111459 T1 AT E111459T1 AT 89201879 T AT89201879 T AT 89201879T AT 89201879 T AT89201879 T AT 89201879T AT E111459 T1 ATE111459 T1 AT E111459T1
Authority
AT
Austria
Prior art keywords
lactonization
mevin
analogues
acids
analogs
Prior art date
Application number
AT89201879T
Other languages
English (en)
Inventor
Laszlo R Treiber
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22827965&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE111459(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE111459T1 publication Critical patent/ATE111459T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AT89201879T 1988-07-19 1989-07-17 Verfahren zur lactonisierung von mevinsäuren und deren analogen. ATE111459T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/221,475 US4916239A (en) 1988-07-19 1988-07-19 Process for the lactonization of mevinic acids and analogs thereof

Publications (1)

Publication Number Publication Date
ATE111459T1 true ATE111459T1 (de) 1994-09-15

Family

ID=22827965

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89201879T ATE111459T1 (de) 1988-07-19 1989-07-17 Verfahren zur lactonisierung von mevinsäuren und deren analogen.

Country Status (26)

Country Link
US (1) US4916239A (de)
EP (1) EP0351918B1 (de)
JP (3) JPH0273078A (de)
KR (1) KR970011286B1 (de)
CN (1) CN1022831C (de)
AT (1) ATE111459T1 (de)
AU (1) AU609319B2 (de)
CA (1) CA1287639C (de)
CS (1) CS274640B2 (de)
CY (1) CY1813A (de)
DE (1) DE68918191C5 (de)
DK (1) DK173115B1 (de)
ES (1) ES2058475T3 (de)
FI (1) FI92695C (de)
HK (1) HK136894A (de)
HR (1) HRP930685B2 (de)
HU (2) HU202511B (de)
IE (1) IE64304B1 (de)
IL (1) IL90925A (de)
LV (1) LV11033B (de)
NO (1) NO172800C (de)
NZ (1) NZ229879A (de)
PT (1) PT91191B (de)
SI (1) SI8911362A (de)
YU (1) YU47492B (de)
ZA (1) ZA895458B (de)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916239A (en) * 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
GB9007738D0 (en) * 1990-04-05 1990-06-06 British Bio Technology Compounds
US5223415A (en) * 1990-10-15 1993-06-29 Merck & Co., Inc. Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid)
US5250435A (en) * 1991-06-04 1993-10-05 Merck & Co., Inc. Mutant strains of Aspergillus terreus for producing 7-[1,2,6,7,8,8a(R)-hexa-hydro-2(S),6(R)-dimethyl-8(S)-hydroxy-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid),I)
AU660132B2 (en) * 1992-12-21 1995-06-08 Bayer Aktiengesellschaft Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridine
WO1994016693A1 (en) * 1993-01-19 1994-08-04 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
IN186879B (de) * 1997-10-28 2001-12-01 Ranbaxy Lab Ltd
IN186880B (de) * 1997-10-28 2001-12-01 Ranbaxy Lab Ltd
ZA9810764B (en) * 1998-04-22 1999-08-13 Ranbaxy Lab Ltd An improved process of lactonization in the preparation of statins.
CA2240983A1 (en) 1998-06-18 1999-12-18 Yong Tao Process to manufacture simvastatin and intermediates
HUP0103021A3 (en) * 1998-12-10 2002-04-29 Kaneka Corp Process for producing simvastatin derivatives
SK282679B6 (sk) * 1999-04-16 2002-11-06 Biotika, A. S. Spôsob izolácie lovastatínu z vyfermentovanej pôdy
AU5705000A (en) * 1999-06-29 2001-01-31 Kaneka Corporation Process for selective lactonization
CA2388182A1 (en) 1999-10-27 2001-05-03 Merck & Co., Inc. Lactonization process
TR200403001T3 (tr) 2000-03-03 2005-02-21 Plus Chemical, S.A. Lovastatin ve simvastatinin, azaltılmış dimerik katışkı seviyelerine sahip olacak şekilde arıtılması için bir işlem
NL1017548C2 (nl) * 2001-03-09 2002-09-10 Synthon Bv Een lactonisatie proces.
US6797831B2 (en) * 2001-05-18 2004-09-28 Aurobindo Pharma Limited Process for lactonization to produce simvastatin
KR100407758B1 (ko) 2001-08-27 2003-12-01 씨제이 주식회사 스타틴의 제조에 있어서 락톤화 방법
KR100502834B1 (ko) * 2002-03-25 2005-07-20 보령제약 주식회사 개선된 락톤화 반응에 의한 심바스타틴의 제조방법 및이의 정제방법
US20050113577A1 (en) * 2002-04-16 2005-05-26 Karki Shyam B. Solid forms of slats with tyrosine kinase activity
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
ATE407670T1 (de) 2002-12-20 2008-09-15 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
CA2515179A1 (en) 2003-02-11 2004-08-26 Ferenc Korodi Process for preparing simvastatin having controlled ranges of simvastatin dimer content
AU2004266740B2 (en) 2003-08-21 2010-08-26 Merck Frosst Canada Ltd Cathepsin cysteine protease inhibitors
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
ATE414071T1 (de) * 2004-03-30 2008-11-15 Lupin Ltd Verbessertes verfahren zur herstellung von 4- hydroxypyran-2-onderivaten
AU2004323102A1 (en) * 2004-09-08 2006-03-16 Jubilant Organosys Limited An improved process for lactonization in the preparation of statins
EP1807070A1 (de) * 2004-09-29 2007-07-18 Schering Corporation Kombinationen aus substituierten azetidinonen und cb1-antagonisten
WO2006059346A2 (en) * 2004-12-01 2006-06-08 Morepen Laboratories Limited An improved process for lactonization to produce highly pure statins
EP1827421B1 (de) 2004-12-09 2017-09-27 Merck Sharp & Dohme Corp. Östrogenrezeptormodulatoren
SI1855674T1 (sl) 2005-03-02 2014-10-30 Merck Sharp & Dohme Corp. Sestavek za inhibicijo katepsina k
EP1888050B1 (de) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. Cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropansäure zur Behandlug von Krebs
EP1741427A1 (de) 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmazeutische Zusammensetzung enthaltend Simvastatin und Ezetimibe
WO2007020079A2 (en) * 2005-08-17 2007-02-22 Synthon B.V. Orally disintegratable simvastatin tablets
PE20070427A1 (es) 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
US20070117996A1 (en) * 2005-11-21 2007-05-24 Srinivasulu Gudipati Process for preparing simvastatin
US20070161578A1 (en) * 2005-12-21 2007-07-12 Hwa Joyce J Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist
JP2009521445A (ja) * 2005-12-21 2009-06-04 シェーリング コーポレイション Ｈ３アンタゴニスト／逆アゴニストと食欲抑制剤との組み合わせ
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
PL2010528T3 (pl) 2006-04-19 2018-03-30 Novartis Ag 6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r
WO2008030382A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
EP2698157B1 (de) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Verfahren zur Behandlung von Fettsäure-Synthese-Hemmern
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2805945B1 (de) 2007-01-10 2019-04-03 MSD Italia S.r.l. Amidsubstituierte Indazole als Poly-(ADP-Ribose)-Polymerase (PARP)-Hemmer
ES2431163T3 (es) 2007-03-01 2013-11-25 Novartis Ag Inhibidores de PIM quinasa y métodos para su uso
ES2452349T3 (es) 2007-05-21 2014-04-01 Novartis Ag Inhibidores de CSF-1R, composiciones, y métodos de uso
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US20090048335A1 (en) * 2007-08-17 2009-02-19 Venkata Naga Mandava Process for preparing simvastatin
PT2222636E (pt) 2007-12-21 2013-07-16 Ligand Pharm Inc Moduladores seletivos de recetores de andrógeno (sarms) e suas utilizações
US8414958B2 (en) * 2008-02-27 2013-04-09 Thommen Medical Ag Implant and method for the manufacture thereof
EP2204170A1 (de) 2008-12-01 2010-07-07 LEK Pharmaceuticals D.D. Pharmazeutische Zusammensetzung mit Ezetimibe und Simvastatin
EP2216016A1 (de) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung, die Ezetimib umfasst
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
EP2488028B1 (de) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Substituierte piperidine zur erhöhung der p53-aktivität und ihre verwendung
CN104098537A (zh) * 2009-11-20 2014-10-15 北大医药股份有限公司 制备他汀类化合物的内酯化方法
CN101704808A (zh) 2009-11-20 2010-05-12 西南合成制药股份有限公司 制备他汀类化合物的内酯化方法
EP2368543A1 (de) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Verfahren zur Herstellung einer granulierten pharmazeutischen Zusammensetzung mit Simvastatin und/oder Ezetimibe
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN107090456B (zh) 2010-08-02 2022-01-18 瑟纳治疗公司 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
JP2013537423A (ja) 2010-08-17 2013-10-03 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (de) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Kondensierte pyrazolderivate als neue erk-hemmer
CA139852S (en) 2010-10-15 2011-11-23 Reno de Medici SpA Christmas tree
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
EP2699568A1 (de) 2011-04-21 2014-02-26 Piramal Enterprises Limited Kristalline form eines morpholinsulfonylindolderivat-salzes und verfahren zu seiner herstellung
WO2013031729A1 (ja) 2011-08-26 2013-03-07 国立大学法人大阪大学 糖尿病性心血管合併症の予防・治療剤
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2597092A1 (de) 2011-11-24 2013-05-29 Sterling Biotech Limited Verfahren zum Reinigen von Lovastatin
EP2844261B1 (de) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. Sina-zusammensetzungen
CN105050598B (zh) 2012-09-28 2018-04-27 默沙东公司 作为erk抑制剂的新型化合物
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (de) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Kreisförmige polynukleotide
EP3055314B1 (de) 2013-10-08 2018-09-12 Merck Sharp & Dohme Corp. Cathepsin-cystein-protease-inhibitoren
WO2015051479A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
US10441567B2 (en) 2014-01-17 2019-10-15 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
WO2015120580A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
EP3706742B1 (de) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5-inhibitoren
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3833667B1 (de) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5-inhibitoren
EP3833668B1 (de) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5-inhibitoren
WO2020033285A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
MX2021012690A (es) 2019-04-19 2022-01-31 Ligand Pharm Inc Formas cristalinas y metodos para producir formas cristalinas de un compuesto.
EP4076460B1 (de) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidin]-derivate als prmt5 inhibitoren zur behandlung von krebs
JP7589247B2 (ja) 2019-12-17 2024-11-25 メルク・シャープ・アンド・ドーム・エルエルシー Ｐｒｍｔ５阻害剤
WO2021126728A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2024180169A1 (en) 2023-03-02 2024-09-06 Carcimun Biotech Gmbh Means and methods for diagnosing cancer and/or an acute inflammatory disease
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA81703B (en) * 1980-02-04 1982-09-29 Merck & Co Inc New antihypercholesterolemic compounds,intermediates and processes
JPS5948418A (ja) * 1982-09-10 1984-03-19 Sankyo Co Ltd 高血清過酸化脂質血症治療剤
US4582915A (en) * 1983-10-11 1986-04-15 Merck & Co., Inc. Process for C-methylation of 2-methylbutyrates
US4611068A (en) * 1984-11-19 1986-09-09 Merck Frosst Canada, Inc. Process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein
US4611067A (en) * 1985-01-31 1986-09-09 Merck & Co., Inc. Process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein
US4772626A (en) * 1986-01-31 1988-09-20 Merck & Co., Inc. Antihypercholesterolemic compounds
PT85109A (en) * 1986-06-23 1987-07-01 Merck & Co Inc Process for the preparation of hydroxy-tetrahydropyranone derivatives or corresponding ring opened dihydroxy acids which are hmg-coa reductase inhibitors
US4857546A (en) * 1988-01-07 1989-08-15 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4916239A (en) * 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof

Also Published As

Publication number Publication date
NO172800C (no) 1993-09-08
FI92695B (fi) 1994-09-15
HUT50804A (en) 1990-03-28
IL90925A (en) 1993-04-04
SI8911362A (en) 1997-02-28
HK136894A (en) 1994-12-09
CS274640B2 (en) 1991-09-15
ES2058475T3 (es) 1994-11-01
KR910002828A (ko) 1991-02-26
IE892324L (en) 1990-01-19
HRP930685B1 (en) 1999-06-30
NO892938D0 (no) 1989-07-17
AU3824089A (en) 1990-01-25
PT91191A (pt) 1990-02-08
PT91191B (pt) 1995-03-01
AU609319B2 (en) 1991-04-26
EP0351918A1 (de) 1990-01-24
LV11033B (en) 1996-06-20
CY1813A (en) 1995-10-20
DK354189A (da) 1990-01-22
LV11033A (lv) 1996-02-20
US4916239A (en) 1990-04-10
NO892938L (no) 1990-01-22
HU210533A9 (en) 1995-04-28
DK173115B1 (da) 2000-01-31
NZ229879A (en) 1991-12-23
CS435489A2 (en) 1990-12-13
FI893363A7 (fi) 1990-01-20
JPH07196642A (ja) 1995-08-01
NO172800B (no) 1993-06-01
JPH09188672A (ja) 1997-07-22
HRP930685A2 (en) 1998-06-30
ZA895458B (en) 1990-03-28
JPH0575752B2 (de) 1993-10-21
DE68918191D1 (de) 1994-10-20
DE68918191T2 (de) 1995-03-02
YU47492B (sh) 1995-10-03
IE64304B1 (en) 1995-07-26
HRP930685B2 (hr) 2006-11-30
JP2718422B2 (ja) 1998-02-25
YU136289A (en) 1991-02-28
DE68918191C5 (de) 2005-06-09
FI893363A0 (fi) 1989-07-11
KR970011286B1 (ko) 1997-07-09
IE892324A1 (en) 1991-06-19
FI92695C (fi) 1994-12-27
IL90925A0 (en) 1990-02-09
DK354189D0 (da) 1989-07-18
EP0351918B1 (de) 1994-09-14
CN1039420A (zh) 1990-02-07
CN1022831C (zh) 1993-11-24
CA1287639C (en) 1991-08-13
JPH0273078A (ja) 1990-03-13
HU202511B (en) 1991-03-28

Similar Documents

Publication Publication Date Title
ATE111459T1 (de) Verfahren zur lactonisierung von mevinsäuren und deren analogen.
HUT63419A (en) Process for producing mercaptoacetamide derivatives of pyrrolo-, pyrido- and oxazinobenzazepine having encephalinase- and angiotensin-converting enzyme-inhibiting activity
DE68913714D1 (de) Verfahren zur Herstellung von ungesättigter Carbonsäure oder ihrem Ester.
DE69016946D1 (de) Verfahren zur Herstellung von 4-O-Dopaminphosphaten und Dopaminderivate.
ATE179169T1 (de) Prostaglandinanaloge
ATE218131T1 (de) Verfahren zur herstellung von mono-n- substituierten tetraazamakrocyclen
DE69007599D1 (de) Verfahren zur Racemisierung optisch aktiver Carbonsäureester.
DE69227819D1 (de) Verfahren zur Veresterung von Salzen von Carbonsäuren
DE58907973D1 (de) Verfahren zur Desodorierung von Fettsäureestergemiscchen.
DE59007810D1 (de) Verfahren zur enzymatischen Spaltung von 2-Arylpropionsäurevinylestern.
DE3866442D1 (de) Zwischenprodukte und verfahren zur herstellung von hmg-coa-reduktasehemmern.
DE3891362T1 (de) Verfahren zur erzeugung von massenstahl
DE68926922D1 (de) Verfahren zur Herstellung von L-alpha-Aminosäuren
AT384222B (de) Verfahren zur herstellung von 7-amino-3alkoxymethyl-3-cephem-4-carbonsaeuren
DE68920948D1 (de) Verfahren zur Racemisierung von Tetrahydrfuran-2-carbonsäure.
DE59008704D1 (de) Verfahren zum Herstellen von cyclischen Kohlensäureestern.
ATE110720T1 (de) Verfahren zur herstellung von 2-mercapto-4-methyl-1,3-thiazol-5-yl-essigsäure und deren ester.
DE69400716D1 (de) Verfahren zur Hydroxykarbonylierung von laktonen
ATE132846T1 (de) Verfahren zum herstellen von estern der halomaleinsäure und halofumarsäure
DE59304167D1 (de) Mikrobiologisches Verfahren zur Herstellung von 5-Hydroxy-2-pyrazincarbonsäure
DE69005317D1 (de) Verfahren und Zwischenprodukte zur Herstellung von Isopropylestern von 3S-amino-2R-hydroxyalkansäuren.
DE59203987D1 (de) Verfahren zur Reinigung von Tetrahydropyran-4-carbonsäureestern.
DE59308560D1 (de) Verfahren zur Phlegmatisierung von 1,2-Naphthochinon-2-diazidsulfonsäureestern

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EETV Partially withdrawn
REN Ceased due to non-payment of the annual fee